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Introduction
Narcolepsy is a chronic sleep disorder caused by a 
deficiency in hypothalamic hypocretin neurotrans-
mission, through a selective loss of hypocretin pro-
ducing neurons [1-3]. This very specific mechanism 
of neural destruction potentially indicates an auto-
immune process.
According to the International Classification of 
Sleep Disorders–second edition (ICSD2) narcolepsy 
and idiopathic hypersomnia are neurological disor-
ders characterized by a clinically significant com-
plaint of excessive daytime sleepiness that is neither 
explained by circadian sleep disorder, sleep-disorder 
breathing or sleep deprivation, nor is it caused by a 
medical condition disturbing sleep [4]. The diagno-
sis of these disorders is based on sleep studies by 
nocturnal polygraphic sleep recording and consecu-
tive Multiple Sleep Latency Test (MSLT), which ob-
jectively quantifies daytime sleepiness. 
Concerning these sleep disorders, narcolepsy is 
a chronic neurological disorder characterized by 
excessive daytime sleepiness that may lead to ‘sleep 
attacks’, hypnagogic hallucinations, sleep paralysis, 
and in some cases abnormal REM sleep events. 
Cataplexy –characterized by sudden loss of muscle 
tone frequently triggered by an emotional stimu-
lus– is a key feature on diagnosis. One of the possi-
ble main causes for narcolepsy with cataplexy (NC) 
is the loss of hypothalamic hypocretin-producing 
neurons. This specific depletion is present in more 
than 98% of NC patients carrying HLA-DQB1*06:02 
allele, frequently in linkage disequilibrium with 
HLA-DRB1*15. This hypocretin-HLA association 
supports the hypothesis that narcolepsy has an au-
toimmune origin [5]. 
The abnormalities of REM sleep and excessive 
daytime sleepiness can be the consequence of the 
loss of hypothalamic neurons, and subsequent defi-
ciency in the hypocretin production [1,2,5-7].
Idiopathic hypersomnia (IH) is a disorder that 
closely resembles narcolepsy syndrome, and its 
presumed causes lay in the central nervous system. 
It is also characterized primarily by severe excessive 
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Introduction. The determination of human leukocyte antigen (HLA) class II genotype is widely used to confirm the diagnosis of 
narcolepsy with or without cataplexy. The HLA genotyping is reliable, easy to perform and reassures the clinician. It is also less 
invasive than other methodologies and is in accordance with the autoimmune hypothesis for the origin of narcolepsy. 
Aim. To assess the usefulness of genetic markers (HLA) in the differential diagnosis between different sleep disorders and 
their relevance in the context of our population. 
Subjects and methods. We analyzed a cohort of 113 patients with episodes of daytime sleepiness, 38 patients were 
classified as narcolepsy with cataplexy, 13 as narcolepsy and 62 as hypersomnia/idiopathic hypersomnia. A control 
population of 206 reportedly healthy individuals from the same geographic origin was used. 
Results. The HLA-DQB1*06:02 allele frequency was overrepresented in patients with narcolepsy and narcolepsy with 
cataplexy (46% and 71% respectively vs. 16% in control population), with a value of p = 4.53–13 for narcolepsy with cataplexy. 
The HLA-DQB1*02 frequency was increased in the population with hypersomnia when compared with the control 
population (55% vs. 34%; p = 0.004). 
Conclusions. Genetic characterization has the potential to enhance the ability to carry out differential diagnosis among 
diverse excessive daytime sleepiness phenotypes, corresponding to diverse entities with different biological mechanisms.
Key words. HLA-DQB1*06:02. Hypocretin. Idiopathic hypersomnia. Narcolepsy. Narcolepsy with cataplexy. Sleep disorders. 
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daytime sleepiness, but without cataplexy. Differ-
ently to narcolepsy, the sleep naps on hypersomnia 
are not refreshing [4,5]. 
Epidemiological studies show that narcolepsy af-
fects approximately 0.02% to 0.05% of the European 
population [4,5]. Meanwhile, the frequency of hy-
persomnia in the same population has extreme val-
ues of 4% to 26% [8-10].
HLA class II genotyping is widely used to con-
firm the diagnosis of narcolepsy with or without 
cataplexy. Studies carried out in the 80’s and 90’s 
demonstrated that genetic markers, particularly 
HLA-DR2 (HLA-DRB1*15) and later DQB1*06:02 
allele, are strongly associated with susceptibility to 
narcolepsy and NC in non-familial cases [11,12].
The first studies conducted in a cohort of 37 in-
dividuals from European descendant, described 
that all NC patients expressed the HLA-DR2 allele 
[11]. In 1997, Mignot et al studied a population of 
509 patients (421 with NC and 88 with narcolepsy) 
and reported that DQB1*06:02 allele was a more 
sensitive marker for narcolepsy than DRB1*15, 
across all ethnic groups [12]. In 2001 a multi-ethnic 
study comprised by 420 subjects with cataplexy (77 
Afro-Americans, 238 Caucasians, and 105 Japa-
nese), demonstrated that HLA-DQB1*06:02 (but 
not HLA-DRB1*15:01) homozygosity increases sus-
ceptibility for NC [13]. Mignot et al [12] also report-
ed the contribution of the HLA system to the sever-
ity of narcolepsy syndrome. He observed that 76.1% 
of NC patients were positive for HLA-DQB1*06:02, 
but when the severity of catapletic attacks was con-
sidered, the HLA-DQB1*06:02 frequency was 94.8% 
in severe cases and 54.2% in the mild ones.
The correlation between HLA-DQB1*06:02 and 
cataplexy was elegantly demonstrated by Okun et al 
[14]. He studied 482 narcoleptic patients and pro-
posed that the presence of this allele correlates with 
older patients, with earlier onset of symptoms and 
more severe and typical symptoms of cataplexy (for 
example triggered by joking or strong emotions) 
and finally with polysomnographic features. He 
noted that 2/3 of all HLA-DQB1*06:02 narcoleptic 
patients experienced cataplexy triggered by strong 
emotions. In this context he proposed that deter-
mining this allele in narcoleptic patients could be 
an alternative to invasive methods to validate cata-
plexy diagnosis [14].
One of the most interesting aspects in this study 
was indeed the detection of a high correlation be-
tween HLA-DQB1*06:02 positivity and cataplexy. 
92-93% of the narcoleptic patients who had their 
cataplexy attacks triggered by strong emotions 
were HLA-DQB1*06:02. This confirmed the allele 
in question as a specific marker for defining genu-
ine cataplexy in narcolepsy [14].
More recent studies showed that the frequency 
of HLA-DQB1*06:02 was different in children and 
adults with narcolepsy with and without cataplexy. 
This difference varied between 93.7% (adults) vs. 
92.6% (children) with NC, and 78.6% in adults vs. 
52.9% in children with narcolepsy without cata-
plexy [15]. 
In 2007, Hong et al studied 163 Korean patients 
with daytime somnolence (79 with NC; 22 with 
narcolepsy; 19 IH; 43 complex cases) and 211 con-
trols, and confirmed that hypocretin deficiency 
correlates with DQB1*06:02. He observed that 81% 
of the NC group had simultaneously low/absent 
levels of hypocretin and DQB1*06:02 positivity [16], 
providing an alternative way to the more invasive 
medical techniques. 
In spite of the wide range of frequencies of these 
alleles observed in populations of diverse origins, it 
has been considered since then, that their presence 
add value to the diagnosis of sleep disorders. The 
increased use of HLA genotyping was the result of 
three convergent reasons:
– The method is reliable, easy to perform and re-
assures the clinician.
– The assay is less invasive than other methodolo-
gies.
– The wide acceptance of the hypothesis of an au-
toimmune origin for narcolepsy (a clinical field 
in which the relevance of the HLA system is gen-
erally accepted).
This last reason finds support in the virtually absent 
levels of hypocretin peptides in the cerebrospinal 
fluid of patients with NC, as reported by Hong et al 
[16], which is postulated to be due to the autoim-
mune destruction of hypocretin producing neurons 
[2,17]. In fact, it was demonstrated that approxi-
mately 90% of the hypocretin producing neurons 
are lost in human NC [17]. According to Jones et al 
[18] and Siebold et al [19], this autoimmune pro-
cess may be the result of the conformation of the P4 
pocket (in the 13β and 26β positions) in the tri-di-
mensional molecular structure of the DQB1*06:02, 
that is claimed to be responsible for hypocretin 
peptide binding. 
The genetic susceptibility factors underlying 
sleep disorders (narcolepsy, NC and IH) might be 
useful tools in a clinical setting. With this work we 
evaluated the contribution of genetic markers 
(HLA) to the differential diagnosis between NC, 
narcolepsy without cataplexy and IH, in a sleep pa-
tient population from the north of Portugal.
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Patients and methods
A cohort of 113 patients complaining of periods of 
excessive daytime somnolence was observed at the 
Sleep Outpatient Clinic of Hospital Santo António/
CHP. Patients were evaluated in a standard protocol 
of clinical, night sleep polygraphic recording, MSLT 
on the following day, and blood sampling. 
Peripheral blood samples (10 mL) from sleep pa-
tients and controls were collected in EDTA. The ge-
nomic DNA was obtained from proteinase-K treat-
ed peripheral blood leukocytes with a salting-out 
procedure [20]. DNA was amplified by PCR with 
sequence-specific primers (PCR-SSP) for the HLA-
DQB1 gene, based on methods and primer se-
quence previously described [21]. PCR products 
were visualized under ultra violet light after elec-
trophoretic separation on 1.5% agarose gel contain-
ing ethidium bromide. Genotypes were deduced 
from the amplification patterns.
The medical records of all patients were reviewed 
by the participating clinicians and confirmed by the 
study coordinator, clinical reevaluation of the pa-
tients was considered if necessary. The patients were 
then classified as NC, narcolepy or IH (according to 
ICSD2): 38 had NC (age at testing: mean, 32.8 years; 
median, 30 years); 13 had narcolepsy (age at testing: 
mean, 34.2 years; median, 36 years); 62 patients had 
IH (age at testing: mean, 38.2 years; median, 40 
years). A control population (CP) of 206 reportedly 
healthy individuals from the same geographic ori-
gin was used. 
HLA-DQB1 phenotype frequencies were deter-
mined by direct counting. HLA frequencies in pa-
tients and controls were compared using the Pear-
son chi-square test or the Fisher’s exact test as ap-
propriate. Mean values were compared using the 
Student’s t distribution.
Results
The HLA-DQB1*06:02 allele was overrepresented 
in narcolepsy and NC patients (46% and 71% res-
pectively vs. 16% in control population), and the 
p value was extremely significant for NC (Table I). 
HLA-DQB1*02 was also increased in the popula-
tion with IH when compared with CP (55% vs. 34%; 
p = 0.00396). Interestingly the frequency of the 
HLA-DQB1*03 allele was decreased in the NC vs. 
CP group (34% vs. 56%; p = 0.012153). No differen-
ces were found in the HLA-DQB1*06:03 frequency 
between the cohort of patients and the CP (Table I).
The allele frequencies of the CP (n = 206) were 
in accordance with a larger cohort of 2500 individ-
ual’s representatives from the central and south re-
gions of Portugal.
Discussion
The significant association found in this study bet-
ween HLA-DQB1*02 with hypersomnia, not ob-
served in other sleep disorders, allows us to consi-
der this allele a risk factor to this entity, which may 
be useful for the differential diagnosis between hy-
persomnia and narcolepsy. 
The HLA-DQB1*06:02 allele, a susceptibility 
factor for several autoimmune disorders (e.g.: mul-
tiple sclerosis, systemic lupus erythematosus, sar-
coidosis, sclerosing cholangitis), was confirmed as 
a susceptibility allele for NC in our population. The 
Table I. HLA-DQB1* frequencies in Portuguese patients with sleep disorders.
Control population  
(n = 206)
Idiopathic hypersomnia  
(n = 62)
Narcolepsy 
(n = 13)
Narcolepsy-cataplexy  
(n = 38)
n % n % p Odds ratio n % p Odds ratio n % p Odds ratio
HLA-DQB1*02 71 34 34 55 0.00396 2.309 5 38 0.769 1.1883 8 21 0.1044 0.5070
HLA-DQB1*03 116 56 32 52 0.514 0.827 9 69 0.361 1.7456 13 34 0.01215 0.4034
HLA-DQB1*06 86 42 22 35 0.378 0.767 9 69 0.052 3.1395 34 89 6.40–8 11.860
HLA-DQB1*06:02 33 16 5 8 0.115 0.276 6 46 0.0058 4.4935 27 71 4.53–13 12.867
HLA-DQB1*06:03 47 23 9 15 0.158 0.574 2 15 0.532 0.6150 4 13 0.18162 0.5125
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frequency of this allele in our cohort of NC patients 
(71%) is in range with those observed in other stud-
ies (Table II). When the three patients with familial 
history of NC are excluded the DQB1*06:02 fre-
quency increase to 77%. However, this frequency is 
lower than expected when compared with studies 
that considered only patients with severe cataplexy, 
in which frequencies typically vary between 85-
95%. In narcolepsy without cataplexy we also found 
an association with this allele, with a frequency of 
46%, in concordance with previous studies from 
Jeong et al (50.5%) [22] and Mignot et al (40.9%) 
[12]. Still, this frequency is lower than the 78.6% re-
ported in Czech patients [15].
The discrepancies reported of HLA-DQB1*06:02 
prevalence in NC patients in diverse studies, can be 
explained by different population backgrounds or 
disease heterogeneity. In a detailed analysis of the 
study of Okun et al [14], in which this group inves-
tigate a cohort of 484 NC patients from different 
ethnic backgrounds, the authors found the HLA 
DQB1*06:02 allele in 380 (78.5%) out of them. This 
value is lower than the frequently reported ‘more 
than 90% of positive HLA DQB1*06:02 in NC pa-
tients’. A possible explanation of these differences is 
also the presence of diverse elements accompany-
ing the NC phenotype characterization. As stated 
by these authors, the association of the NC popula-
tions with HLA DQB1*06:02 allele increases from 
77.4% to 97.4% in the presence of different cata-
plexy triggers [14]. Concerning the HLA suscepti-
bility alleles, if an individual is homozygous for 
HLA-DQB1*06:02 it has a greater risk than a 
heterozygous individual to develop narcolepsy [23]. 
Furthermore, HLA-DQB1*03:01 has been proposed 
as a second allele for susceptibility to NC [13,24]. 
Our study showed an association between NC and 
HLA-DQB1*03 allele (p = 0.01215) but with a pro-
tective effect. 
In 2007 HLA-DQB1*06:01 has been described 
as a protective allele in a Korean population [16,22]. 
More recently the HLA-DQB1*06:03 allele was also 
considered as a protective factor against NC [25,26], 
but this assumption needs to be explored. In our 
study, the HLA-DQB1*06:03 allele had a lower fre-
quency in the sleep disorders analyzed when com-
pared with our control population, however, we 
found no sign that pointed to a protective role in 
sleep disorders.
The issue of susceptibility/protection alleles on 
narcolepsy and NC should be considered on a 
structural basis of the HLA-DQB1*06 molecule. 
The P4 pocket volume of this molecule appears to 
be central to the positive or negative association 
with narcolepsy [18,19]. The volume of this pocket 
differs significantly between DQB1*06:02 (suscepti-
Table II. Data comparison of referred studies on genetics of sleep disorders.
Studied population Results
Langdon et al [11] 37 patients (European descendants) 37 patients (100%) are HLA-DR2 and DQwl
Mignot et al [12]
509 patients: 421 NC; 88 N  
(different ethnic groups)
Patients positive for DQB1*06:02.  
NC: 76.1% (54.2-94.8%); N: 40.9%
Mignot et al [13]
3 ethnics groups: Japanese, Afro-American,  
European descendants. 1,087 CP; 420 NC
‘Almost all’ narcoleptics are  
DQA1*01:02 and DQB1*06:02
Okun et al [14]
64 Afro-Americans, 353 European descendents,  
32 Asian, 26 Latinos, 9 mix ethnic
NC: 92% DQB1*06:02  
independently of ethnics
Jeong et al [22] Koreans: 56 NC; 16 N HLA-DQB1*06:02 in 89.3% NC vs. 50.0% N (p = 0.003)
Hong et al [16]
Koreans: 163 patients with  
diurnal somnolence (100 N); 211 CP
DQB1*06:02 associated with  
hypocretin deficiency (100% vs. 13%)
Nevsimalova et al [15]
Czech Republic: 148 narcoleptic patients  
(117 adults, 31 children). 109 NC; 39 N
HLA-DQB1*06:02 in NC = 93.7% adults vs.  
92.6% children, and N = 78.6% adults vs. 52.9% children
Present study
Portugal (North): 13 N; 38 NC; 62 IH;  
206 CP
HLA-DQB1*06:02 in 46% N (p = 0.0058),  
71% NC (p = 0.000), 8% IH, 16% CP
CP: control population; IH: idiopathic hypersomnia; N: narcolepsy without cataplexy; NC: narcolepsy with cataplexy.
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bility) and DQB1*06:01 (protection) molecules, and 
this restricts the peptide repertoire that these mol-
ecules can accommodate and present to T cells. 
The HLA-DQB1*06:02 molecule will be responsible 
for hypocretin peptide binding and for the autoim-
mune attack on the hypocretin secreting neurons. 
The HLA-DQB1*06:01 has a significantly smaller 
volume in its P4 pocket, and can’t accommodate 
such peptides. It is possible that the peptide-bind-
ing differences between these two allelic products 
determine whether they confer risk to or protect 
against narcolepsy. Concerning the DQB1*06:03 al-
lele, the configuration of this P4 pocket is exactly 
the same of the DQB1*06:02 allele, so if a protective 
role of this allele exists, some other reason for that 
must be sought [18,19].
Finally, some of the differences found in this 
study and in reported studies (HLA and sleep dis-
orders) could also be due to phenotypic ambiguity. 
As stressed by other authors [14], the clinical pic-
ture of narcolepsy could be different in different age 
groups, which complicates the clinical diagnosis 
that could often be delayed for several years. If this 
is due to a modification of hypocretin levels, by cir-
cadian oscillations or environmental factors (infec-
tions, head trauma, immunization), or to differenc-
es in the regenerative potential of central nervous 
system tissue, is a theme of current research. These 
agents can trigger different clinical responses chang-
ing the phenotype expression. Given those uncer-
tainties, genetic characterization has the potential 
to improve the ability to carry out differential diag-
nosis among diverse excessive daytime sleepiness 
phenotypes, helping in the distinction of diverse 
entities corresponding to fundamentally different 
biological processes.
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Utilidad de la caracterización genética de la narcolepsia y la hipersomnia en la definición del fenotipo: 
estudio en pacientes portugueses
Introducción. La determinación del genotipo de los antígenos leucocitarios humanos (HLA) de clase II es un método muy 
difundido para confirmar el diagnóstico de la narcolepsia, con y sin cataplejía. El genotipado del HLA es fiable, sencillo y 
proporciona seguridad al médico. También es menos invasivo que otros métodos y entronca con la hipótesis autoinmuni-
taria sobre el origen de la narcolepsia. 
Objetivo. Evaluar la utilidad de los marcadores genéticos (HLA) en el diagnóstico diferencial de diferentes trastornos del 
sueño y su relevancia en el contexto de nuestra población. 
Sujetos y métodos. Se analizó una cohorte de 113 pacientes con episodios de somnolencia diurna, 38 de los cuales fueron 
clasificados como afectados por narcolepsia con cataplejía, 13 con narcolepsia y 62 con hipersomnia/hipersomnia idiopá-
tica. La población de control estaba integrada por 206 individuos sanos del mismo origen geográfico. 
Resultados. La frecuencia del alelo HLA-DQB1*06:02 era superior a la habitual en los pacientes con narcolepsia y narco-
lepsia con cataplejía (46% y 71%, respectivamente, frente al 16% en la población control), con un valor de p = 4,53–13 en el 
caso de la narcolepsia con cataplejía. La frecuencia del alelo HLA-DQB1*02 era más elevada en la población con hipersomnia 
en comparación con la población control (55% frente a 34%; p = 0,004). 
Conclusiones. La caracterización genética tiene posibilidades de mejorar el diagnóstico diferencial entre varios fenotipos 
de somnolencia diurna excesiva, que corresponden a diversas entidades con diferentes mecanismos biológicos.
Palabras clave. Hipocretina. Hipersomnia idiopática. HLA-DQB1*06:02. Narcolepsia. Narcolepsia con cataplejía. Trastornos 
del sueño. 
